Heidelberg

• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Recruiting
  2025-523495-23-00 5 2026-06-09 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• Beamion 44: A study to test how well zongertinib is tolerated by people with advanced non-small cell lung cancer with HER2 mutations when gi … Recruiting
  2025-523567-38-00 4 2026-06-02 locally advanced or metastatic NSCLC
• A clinical trial of ifinatamab deruxtecan in people with advanced esophageal cancer (MK-3475-06F) Recruiting
  2026-525213-31-00 4 2026-05-21 Esophageal squamous cell carcinoma
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• L19IL2/TNF in patients with basal cell carcinoma Recruiting
  2025-523230-77-00 4 2026-04-27 Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
• L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting
  2025-523231-19-00 4 2026-04-27 Cutaneous Squamous Cell Carcinoma
• RENEW - A Phase 2 Study of the Safety, Tolerability and Efficacy of LTI-03 in Patients with Idiopathic Pulmonary Fibrosis Recruiting
  2025-520715-13-00 4 2026-04-22 Idiopathic Pulmonary Fibrosis
• A clinical study to test how safe and effective a new inhaled treatment (called L606) is for people with high blood pressure in the lungs du … Recruiting
  2024-517943-29-00 5 2026-04-21 Pulmonary Hypertension associated with interstitial lung disease (WHO
• A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting
  2024-512248-47-00 9 2026-04-15 Non-small Cell Lung Cancer (NSCLC)
• A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation Recruiting
  2025-521521-33-00 10 2026-04-02 Kidney transplant rejection
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting
  2024-519555-28-00 5 2026-03-18 Dravet syndrome
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• A Phase 1/2 study of ALXN2350 in adult participants with BAG3-associated dilated cardiomyopathy Recruiting
  2024-519674-40-00 7 2026-02-05 BAG3 Mutation Associated Dilated Cardiomyopathy
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors Recruiting
  2025-521672-60-00 7 2025-12-19 Metastatic or locally advanced SST2-positive neuroendocrine neoplasms
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and my … Recruiting
  2025-521299-76-00 7 2025-12-18 Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes wi
• Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting
  2025-522455-26-00 9 2025-12-17 Acute Ischemic Stroke
• STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting
  2025-521276-59-00 5 2025-12-16 Autosomal dominant polycystic kidney disease (ADPKD)

Showing 49–72 of 735 trials